Sector News

Sanofi said to cut more than 30 local research jobs

February 23, 2016
Life sciences

French drug maker Sanofi SA, pressing forward with a global realignment, Monday notified about three dozen research and development employees in Massachusetts that their jobs will be eliminated, according to employees.

The jobs are in labs supporting the biosurgery, bone and joint disease, drug delivery discovery, and biomaterial engineering groups that were formerly part of Genzyme Corp., the employees said. Those labs are in Cambridge, Framingham, and Waltham.

Sanofi paid $20.1 billion to acquire Cambridge-based Genzyme in 2011 and has renamed the division Sanofi Genzyme. In a global restructuring that began last summer, Sanofi shifted oversight for research and development jobs in Massachusetts and elsewhere to a corporate research organization based in Paris.

A spokeswoman said Monday that she couldn’t immediately comment on the cuts. Sanofi told its labor unions earlier this month that it is paring about 600 jobs in France. The company has not confirmed cuts at other locations.

By Robert Weisman

Source: Boston Globe

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach